Compare MobilEye Global Inc (MBLY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? MobilEye Global Inc trades at $9.03 (market cap $7.54B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 16.2× MobilEye Global Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| MBLY | VRTX | |
|---|---|---|
Market Cap | $7.54B | $121.95B |
Sector | Technology | Health |
52-Week High | $16.19 | $529.59 |
52-Week Low | $6.56 | $366.54 |
Enterprise Value | $6.19B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $8.95, down 2.93% on the day, with a bearish technical signal and key support at $8. The company reported revenue of $1.89B in 2025 but a net loss of $392M, with profitability metrics deeply negative. Recent news highlights a strategic expansion into a U.S. robotaxi service planned for 2027, alongside a new supply agreement with Stellantis for advanced driver-assistance systems.
The outlook is bifurcated: analyst consensus is bullish with a $10.71 price target (57.69% buy ratings), anticipating growth from autonomous driving initiatives, but high execution risks and persistent losses pose significant challenges. Near-term performance hinges on Q2 2026 earnings due July 23, 2026, with expectations of a decline.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
